Purpose: To assess the long-term safety, efficacy, predictability, and stability of conductive keratoplasty (CK) for the treatment of low to moderate hyperopia and to evaluate the impact of the procedure on the quality of vision.
Setting: University of Crete, Medical School, Vardinoyannion Eye Institute of Crete, Crete, Greece.
Methods: In this prospective nonrandomized noncontrolled single-center study, 38 eyes of 26 patients (13 women and 13 men) were treated for hyperopia with a Refractec ViewPoint CK system and followed for 30 months. Preoperatively, the mean manifest refraction spherical equivalent (MRSE) was +1.89 diopters (D) +/- 0.6 (SD) (range +1.00 to +3.25 D), and the mean follow-up was 30.9 +/- 1.1 months. All eyes were treated with the regular CK nomogram for the treatment of spherical hyperopia. The treatment consisted of 8 to 32 spots applied to the periphery of the cornea. Mean age was 50.3 +/- 8.8 years (range 31 to 71 years). All treated eyes were analyzed for safety, efficacy, predictability, and stability.
Results: At 12 months, the MRSE was -0.06 +/- 0.8 D and at 30 months was -0.02 +/- 0.7 D. At 30 months, the mean MRSE was within +/-0.50 D in 68%, within +/-1.00 D in 92%, and within +/-2.00 D in all eyes. At 30 months, uncorrected visual acuity was 20/20 or better in 52.5% and 20/40 or better in 89% of eyes. No eye lost 2 or more Snellen lines or had an induced cylinder of 2.00 D or greater. The procedure did not cause statistically significant changes in contrast sensitivity.
Conclusion: Results show that CK for low to moderate hyperopia is a safe, effective, predictable, and stable procedure.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcrs.2005.01.032 | DOI Listing |
COPD
December 2025
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.
Methods: We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD.
Osteoarthr Cartil Open
March 2025
The Parker Institute, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Denmark.
Objective: Obesity is a major risk factor for osteoarthritis (OA). Adipose tissues may be linked to OA development through secretion of potential proinflammatory cytokines including neutrophil gelatinase-associated lipocalin (NGAL). Our objective was to assess changes in serum NGAL after a low-calorie diet (LCD) and subsequent glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment.
View Article and Find Full Text PDFCureus
December 2024
Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, PAK.
Background: Breast cancer is one of the most common cancers among Pakistani women. It is mostly diagnosed at stage 2, requiring chemotherapy in certain cases. Chemotherapy is of two types: adjuvant and neoadjuvant.
View Article and Find Full Text PDFHeliyon
January 2025
Tigray Agricultural Research Institute, Mekelle Soil Research Center, Mekelle, Tigray, Ethiopia.
Sesame ( L.) is an important cash crop and plays a vital role in many people's livelihoods in Ethiopia. However, its production is low due to many constraints, and low soil fertility is among the major.
View Article and Find Full Text PDFObjectives: To evaluate the utility of the HAS-BLED bleeding risk-estimation tool to predict for clinically significant postoperative haematuria in patients receiving transurethral resection of prostate (TURP).
Patients And Methods: A single-centre, retrospective cohort analysis of patients underwent TURP from April 2019 to December 2023 for treatment of symptomatic benign prostate hyperplasia. The primary objective was to evaluate reliability of HAS-BLED score in predicting postoperative bleeding event.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!